Doctor on coronavirus: 'We're in an arms race now'
In This Article:
There are signs of hope in the U.S. amid the coronavirus pandemic with more COVID-19 vaccines being approved for emergency use authorization (EUA) by government regulators and the number of vaccinations surpassing the number of total confirmed cases in the country.
At the same time, a new challenge has risen: Mutant (variant) strains of the virus have begun popping up around the globe, most notably in Brazil, South Africa, and the United Kingdom.
“We’re in an arms race now against this virus to see: Can we get people vaccinated quickly enough before these new, more contagious, more transmissible strains really take hold and become the dominant strains?” Dr. Summer Johnson, dean of health sciences at the University of New Haven, said on Yahoo Finance Live (video above). “Vaccination is one key component of that.”
The challenge has been the rollout of the vaccine. In the U.S. so far, however, only 7.6% of the public (slightly more than 26 million people) have received at least one dose of a vaccine. However, the country finally surpassed the number of coronavirus cases with vaccines.
The goal is for the country to get to administering 2 million doses a week in the near future, which Johnson still thinks is a possibility.
“What we’re heaving at the local level is that states and counties have the vaccination sites ready to go,” Johnson said. “I think the other piece is making sure we also have enough vaccinations to get the shots in the arms. If we can figure those two things out, we can hit the 2 million a week goal pretty easily.”
‘Think just like we do with the flu vaccine every year’
Pfizer (PFE) and Moderna (MRNA) have begun distributing their vaccines to the public while Johnson & Johnson (JNJ) and Novavax (NVAX) await government approval.
To reach herd immunity, which would allow a return to relative normalcy for much of society, an estimated 80 to 90% of the public needs to be vaccinated.
“The faster we can get people to having some kind of immunity … even though we’ve seen some of these vaccines now that are being studied and being tested against these new strains aren’t quite as effective as they are against some of those original strains, they are still effective,” Johnson said. “It’s going to slow the spread of those more aggressive mutants which will mean ultimately, we’re going to be able to get control of the overall spread of the virus.”
And though vaccinating more people means containing the spread of the virus, Johnson said the coronavirus is still likely here to stay in a mitigated form.
“Think just like we do with the flu vaccine every year, we have to do our best guess and our predictions about what are the dominant strains in any given year or in any given country likely to be,” Johnson said, “and to include those strains, that mRNA, into those vaccines if we’re talking about Pfizer or Moderna, so I think we can do that.”